Nevertheless, the landscape of therapeutic strategies targeting Notch signaling is rapidly expanding (reviewed in [242]) and may provide novel approaches, e.g., targeting DLL4-NOTCH1 interactions [146,243,244], or combinational therapies [245] to hit the Notch pathway in CLL. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.